Nivolumab for recurrent or metastatic head and neck cancer patients with non-squamous cell carcinoma and/or a primary subsite excluded from CheckMate141, a retrospective study

Autor: Ueda, Yuri, Okano, Susumu, Enokida, Tomohiro, Fujisawa, Takao, Ito, Kazue, Sato, Masanobu, Tanaka, Hideki, Wada, Akihisa, Tahara, Makoto
Zdroj: In Oral Oncology July 2022 130
Databáze: ScienceDirect